NHS Doncaster CCG becomes the 100th NHS Clinical Commissioning Group (CCG) to roll out the Hearst Health International patient-specific prescribing solution, FDB OptimiseRx, to all 43 member GP practices. The announcement was made today by Jeff Dienhart, Senior Managing Director of Hearst Health International.
FDB OptimiseRx works by providing patient-specific, evidence-based medication guidance messages within the GP prescribing workflow. The messages are specific to the individual patient record within EMIS Web, TPP SystmOne and Microtest Evolution, enabling GPs and prescribers to make real-time optimal prescribing decisions that are clinically appropriate and cost-effective for the patient in consultation.
Jeff Dienhart said: “Hearst Health International has a proud history in advancing independent, unbiased, and evidence-based care guidance solutions for supporting safe medication decisions. We are extremely proud that 100 CCGs have now selected to implement FDB OptimiseRx in the three years since launch; a vote of confidence to its relevance and value in supporting clinicians to improve medication outcomes. Our customers benefit from the delivery of patient-specific quality, safety and cost guidance provided through deep integration with the patient medical record. This is truly a great milestone, and we look forward to working with the NHS and health IT suppliers to further support the uptake of appropriate medicines use and safety guidance across the country.”
In 2016, more than 80 million medicines optimisation recommendations were presented to GPs and prescribers across the NHS in England, reaching more than 24 million patients. Jeff continues: “The prescribing community, using FDB OptimiseRx, have been able to improve both the appropriateness and financial impact of drug use, by better guiding the most cost-effective, clinically-optimal medication choices at the point of prescribing.”
Jeremy Bradley, Prescribing Lead GP Doncaster CCG said: “Doncaster CCG has chosen to use FDB OptimiseRx to streamline GP working around best practice, safety and costs. We are due to go live in April 2017 and have had a very successful trial. Feedback we received from our trial found that clinicians thought the workflow was simple and easy to use; 78% of clinicians ranked best practice and safety guidance messages as the most important feature.”
Jeremy continues: “FDB OptimiseRx was chosen by our CCG due to its patient-specific recommendations, this means that only appropriate messages are shown in a consultation. The solution also saves time by automatically changing a prescription if an optimised medication is chosen which we have found particularly useful. We believe that FDB OptimiseRx will help increase prescribing in accordance to our local formulary and improve patient safety. Savings made through prescribing, with the help of FDB OptimiseRx, will contribute towards the sustainability of the CCG and the reinvestment of monies saved.”